Immunology and Immunotherapy 101 for the Non-Immunologist

Michael J. Gough, PhD Earle A. Chiles Research Institute at Providence Cancer Center






Disclosures


- Consulting Fees: AstraZeneca, Pfizer, Regeneron Pharmaceuticals, Inc.
- Contracted Research: Bristol-Myers Squibb
- I will be discussing non-FDA approved treatments during my presentation.



Immune cells are derived from stem cells in the bone marrow



Myeloid cells




- Derived from a common progenitor
- Comprises most of the cells of the innate immune system
- Functional maturation may happen in tissue in response to danger signals



Granulocytes

Short-lived cells that possess granules containing degradative enzymes and anti-microbial substances




Neutrophils, eosinophils and basophils are sometimes referred to as polymorphonuclear leukoyctes (PMNs)



Phagocytes


Neutrophils, macrophages and dendritic cells




Dendritic cells and macrophages are two types of professional antigen presenting cells (APCs)




Lymphocytes





Note: Immmune cells and lymphoid aggregates are also found througout the body

Infectious agents first activate innate immune cells resulting in an inflammatory response




Cytokines are proteins that immune cells use to communicate/regulate other immune cells, not all cytokines are inflammatory

Chemokines are a group of cytokines that attract other immune cells



Innate responses are initiated upon recognition of "danger signals" by pattern recognition receptors (PRRs)



"Danger signals"

- Pathogen-associated molecular patterns (PAMPs)
 - Bacteria proteins
 - viral DNA/RNA
- Damage-associated molecular patterns (DAMPs)
 Products of dying cells


Types of PRRs

- Toll-like receptors (TLR)
- C-type lectin receptors
- NOD-like receptors (NLRs)
- RIG-I-like receptors

Receptors can be on the cell surface or intracellular (NLRs)




DCs are important for initiating adaptive immune responses






Antigen processing and presentation

Professional APCs present Ag to naïve T cells and induce activation





MHC Class I presents peptide antigens to CD8 T cells




Major Histocompatibility Complex (MHC) Class I

- Expressed by all nucleated cells
- Presents peptides derived from endogenous proteins
- MHC Class I proteins are also recognized by NK cells



MHC Class II presents antigens to CD4 T cells




Major Histocompatibility Complex (MHC) Class II


- Typically expressed by professional APCs
- Presents peptides derived from exogenous proteins



Adaptive immune responses




Antigen receptors






Antigen recognition by antibodies

Ab recognizes portions of proteins in native structures, not processed proteins (may not be continuous portion of protein)






T cell receptors (TCRs) recognize processed proteins presented by MHC



MHC = Major Histocompatibility Complex



Generating lymphocytes that each have a unique specificity



Generation of vast pool of cells

 Immature cells (non-functional)

Elimination of cells that can recognize self Ags


 One barrier to inducing responses against tumor cells

Mechanism of central tolerance

 Circulating mature naïve cells




Lymphocyte activation




What happens to T cells and B cells after immune response?




Lymphocyte activation



Effector mechanisms of adaptive immunity



Effector mechanisms of adaptive immunity



B Cells

Ab function:


- Neutralize
- Block protein functions
- Promote engulfement
- Induce complementmediated cell lysis

Different classes (isotypes) of Ab

- IgM
- IgG
- IgE
- IgA



Significance of immunological memory



Presents peptides derived from exogenous proteins



To exist, tumors must evolve mechanisms to locally disable and/or evade the immune system.

The goal of immunotherapy, then, is to restore the capacity of the immune system to recognize and reject cancer.

